Investigational Site Number :7240004

Barcelona, Barcelona [Barcelona] 08041

0 studies enrolling now · 8 studies all time

What they study most

Alport Syndrome, Malignant Melanoma, Multiple Sclerosis, Non-squamous Non-small Cell Lung Cancer, Plasma Cell Myeloma, Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Skin, Transplant Rejection

Studies at this site

• A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant — Running, not enrolling
• BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) — Running, not enrolling
• A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) — Stopped early
• Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma — Running, not enrolling
• Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis — Running, not enrolling
• A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) — Stopped early
• Study of Lademirsen (SAR339375) in Patients With Alport Syndrome — Stopped early
• Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA — Stopped early